Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | PREP | P48147 | 3/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16276294 | 0.89 | AADAT (0.40) | AADATKLK7PARP1PRMT5GPR119 | |
| SCHEMBL17396065 | 0.89 | USP30 (0.44) | — | |
| SCHEMBL17396063 | 0.89 | USP30 (0.44) | — | |
| SCHEMBL883261 | 0.89 | USP30 (0.43) | GPR119 | |
| SCHEMBL883274 | 0.89 | USP30 (0.43) | GPR119 | |
| SCHEMBL889395 | 0.89 | AADAT (0.38) | AADATKLK7PARP1PRMT5GPR119 | |
| SCHEMBL13132670 | 0.88 | AADAT (0.44) | AADATTMEM97SIGMAR1PREPACE2 | |
| SCHEMBL889389 | 0.88 | AADAT (0.44) | AADATTMEM97SIGMAR1PREPACE2 | |
| SCHEMBL12295753 | 0.88 | PRMT5 (0.40) | KLK7PRMT5 | |
| SCHEMBL1061828 | 0.88 | TMEM97 (0.48) | AADATTMEM97SIGMAR1PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138215-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138215-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-02 | — | — | US | disclosed |
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303755-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | AADAT 2969/4885KLK7 3500/4885PARP1 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.